{"id":390772,"date":"2017-12-19T00:00:00","date_gmt":"2017-12-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptoon0001-2017-biopharma-multiple-indications-special-topics-immune-checkpoint-inhibitors-in-oncology-g7-2017\/"},"modified":"2026-04-18T23:25:44","modified_gmt":"2026-04-18T23:25:44","slug":"sptoon0001-2017-biopharma-multiple-indications-special-topics-immune-checkpoint-inhibitors-in-oncology-g7-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptoon0001-2017-biopharma-multiple-indications-special-topics-immune-checkpoint-inhibitors-in-oncology-g7-2017\/","title":{"rendered":"Multiple Indications | Special Topics | Immune Checkpoint Inhibitors in Oncology | G7 | 2017"},"content":{"rendered":"<p>Immune checkpoint inhibitors continue to revolutionize the treatment of a wide range of solid-tumor and hematological malignancies, with a growing list of approvals and label expansions. The Immune Checkpoint Inhibitors Special Topics report provides a comprehensive, multi-indication coverage of currently available immune checkpoint inhibitors \u2014 ipilimumab (Bristol Myers-Squibb\u2019s Yervoy), nivolumab (Bristol Myers-Squibb\u2019s Opdivo), pembrolizumab (Merck &#038; Co.\u2019s Keytruda), atezolizumab (Roche\/Genentech\u2019s Tecentriq), avelumab (Pfizer\/Merck KGaA\u2019s Bavencio), and durvalumab\u00a0(AstraZeneca\u2019s Imfinzi)\u00a0\u2014 and examines their ongoing clinical development across oncology. In addition, analysis of late-phase emerging therapies and their future positioning is provided, along with an annualized top-down market forecast. The report also offers an extensive list of agents in early-phase development, as well as an analysis of the most promising novel targets and combination therapies for immune checkpoint inhibitors.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>\u00a0What is the landscape for current immune checkpoint inhibitors in oncology? What are the trends in their ongoing clinical development?<\/li>\n<li>What are the key trends for emerging immune checkpoint inhibitors in late-phase development? How do interviewed experts perceive these therapies?<\/li>\n<li>What is the market outlook for current and emerging immune checkpoint inhibitors across oncology?<\/li>\n<li>What are the therapies and\/or mechanisms of action to watch in the early-phase pipeline?<\/li>\n<li>What is the potential of combinatorial approaches involving immune checkpoint inhibitors?<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390772","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-oncology","biopharma-product-special-topics-other","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390772\/revisions"}],"predecessor-version":[{"id":576764,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390772\/revisions\/576764"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}